Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | RORC | P51449 | 15/20 | 0.60 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628565 | 0.94 | TRPV1 (0.64) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628566 | 0.93 | TRPV1 (0.66) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628277 | 0.92 | TRPV1 (0.64) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13637691 | 0.91 | TRPV1 (0.64) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628399 | 0.91 | TRPV1 (0.64) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628474 | 0.91 | RORC (0.63) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13637694 | 0.91 | TRPV1 (0.62) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628293 | 0.91 | TRPV1 (0.62) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628536 | 0.91 | TRPV1 (0.64) | TRPV1RORCEGLN2EGLN1EGLN3 | |
| SCHEMBL13628414 | 0.90 | RORC (0.58) | TRPV1RORCEGLN2EGLN1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | TRPV1 3411/4885RORC 514/4885EGLN2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.